Polymorphism of the COMT, MAO, DAT, NET and 5-HTT Genes, and Biogenic Amines in Parkinson’s Disease

ISSN: 1875-5488 (Online)
ISSN: 1389-2029 (Print)

Volume 16, 6 Issues, 2015

Download PDF Flyer

Current Genomics

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 69th of 164 in Genetics & Heredity
  • 144th of 291 in Biochemistry & Molecular Biology

Submit Abstracts Online Submit Manuscripts Online

Christian Néri
Institute of Biology Paris-Seine
CNRS UMR 8256 and UPMC
Paris, 75005

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.868
5 - Year: 2.987

Polymorphism of the COMT, MAO, DAT, NET and 5-HTT Genes, and Biogenic Amines in Parkinson’s Disease

Author(s): Jolanta Dorszewska, Michal Prendecki, Anna Oczkowska, Agata Rozycka, Margarita Lianeri and Wojciech Kozubski

Affiliation: Laboratory of Neurobiology, Department of Neurology, Poznan University of Medical Sciences, 49, Przybyszewskiego St. PL 60-355 Poznan, Poland.


Epinephrine (E) and sympathetic nerve stimulation were described by Thomas Renton Elliott in 1905 for the first time. Dopamine (DA), norepinephrine (NE), E, and serotonin (5-HT) belong to the classic biogenic amines (or monoamines). Parkinson’s disease (PD) is among the diseases in which it has been established that catecholamines may account for the neurodegeneration of central and peripheral catecholamine neural systems. PD is a chronic and progressive neurological disorder characterized by resting tremor, rigidity, and bradykinesia, affecting 2% of individuals above the age of 65 years. This disorder is a result of degeneration of DA-producing neurons of the substantia nigra and a significant loss of noradrenergic neurons in the locus coeruleus. In PD and other related neurodegerative diseases, catecholamines play the role of endogenous neurotoxins. Catechol-O-methyltransferase (COMT) and/or monoamine oxidase (MAO) catalyze the metabolism of monoamines. However, the monoamine transporters for DA, NE, and 5-HT namely DAT, NET, and SERT, respectively regulate the monoamine concentration. The metabolism of catecholamines and 5-HT involves common factors. Monoamine transporters represent targets for many pharmacological agents that affect brain function, including psychostimulators and antidepressants. In PD, polymorphisms of the COMT, MAO, DAT, NET, and 5- HTT genes may change the levels of biogenic amines and their metabolic products. The currently available therapies for PD improve the symptoms but do not halt the progression of the disease. The most effective treatment for PD patients is therapy with L-dopa. Combined therapy for PD involves a DA agonist and decarboxylase, MAOs and COMT inhibitors, and is the current optimal form of PD treatment maintaining monoamine balance.

Keywords: COMT, MAO, Monoamine transporters polymorphism, PD.

Purchase Online Order Reprints Order Eprints Rights and Permissions


Article Details

Volume: 14
Issue Number: 8
First Page: 518
Last Page: 533
Page Count: 16
DOI: 10.2174/1389202914666131210210241

Related Journals

Webmaster Contact: urooj@benthamscience.org Copyright © 2015 Bentham Science